Brief: Surface Oncology Inc Reports Quarterly Diluted Net Loss Per Share Of $0.35
09/03/2023 12:36
March 9 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY REPORTS FINANCIAL RESULTS AND CORPORATE
HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2022
* CASH RUNWAY GUIDANCE EXTENDED INTO Q3 OF 2024
* SRF388 CLINICAL PROGRAM ADVANCING WELL; UPDATED CLINICAL
DATA
EXPECTED IN FIRST HALF OF 2023
* AS OF DECEMBER 31, 2022, CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES WERE $124.8 MILLION
* AS OF DECEMBER 31, 2022, CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES WERE $124.8 MILLION
* QTRLY DILUTED NET LOSS PER SHARE OF $0.35
* Q4 EARNINGS PER SHARE VIEW $-0.33 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX73ghMq
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing